GlassScriptPhysician profile
Kelley J Bohm
NPI 1609238443
$2,905.55
in general payments reported to CMS, 2019-2025
25 companies · $852 in 2025
The $852 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $379 · 2020: $90.16 · 2021: $161 · 2022: $428 · 2023: $536 · 2024: $459 · 2025: $852.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,847.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,847.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $972.28 | 2019-2025 | Clareon, Rocklatan, Rhopressa |
| Tarsus Pharmaceuticals, INC. | $318.64 | 2024-2025 | Xdemvy |
| Biotissue Holdings INC. | $224.25 | 2021-2025 | |
| Johnson & Johnson Surgical Vision, INC. | $160.80 | 2023-2025 | Tecnis Simplicity, Tecnis Iol, Veritas Vision System |
| Abbvie INC. | $142.34 | 2019-2025 | Lumigan |
| Sun Pharmaceutical Industries INC. | $132.60 | 2022-2025 | |
| Dompe US, INC. | $129.42 | 2025 | Oxervate |
| Allergan, INC. | $128.52 | 2022 | |
| Mallinckrodt Hospital Products INC. | $104.27 | 2023-2024 | Acthar |
| Ani Pharmaceuticals, INC. | $75.93 | 2025 | Purified Cortrophin Gel, Yutiq |
| Apellis Pharmaceuticals, INC. | $73.17 | 2023-2024 | Syfovre |
| Harrow Eye, LLC | $51.34 | 2024-2025 | Vevye |
| Amgen INC. | $49.74 | 2025 | Tepezza |
| Aerie Pharmaceuticals, INC. | $46.15 | 2021 | |
| Rxsight INC | $42.09 | 2023 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge, Rxsight Injector Handpiece |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iridex Corporation | $41.06 | 2020 | |
| Glaukos Corporation | $37.71 | 2021-2024 | Idose |
| Oyster Point Pharma, INC. | $29.87 | 2025 | Tyrvaya, Ryzumvi |
| Vyera Pharmaceuticals, LLC | $28.32 | 2021 | |
| Ocular Therapeutix, INC. | $28.00 | 2022-2024 | Dextenza |
| Astellas Pharma US INC | $23.62 | 2025 | Izervay |
| Novartis Pharmaceuticals Corporation | $21.56 | 2022 | |
| Bausch & Lomb Americas INC. | $17.98 | 2023 | Vyzulta |
| Sight Sciences, INC. | $14.10 | 2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $11.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelley Bohm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.